title: IL-17 contributes to CD4-mediated graft-versus-host disease.
abstract: CD4(+) interleukin-17 (IL-17)(+) T cells (Th17 cells) have been implicated in allograft rejection of solid organs and several autoimmune diseases. However, the functional role of Th17 cells in the development of acute graft-versus-host disease (GVHD) has not been well-characterized. We detected significant numbers of alloreactive CD4(+) donor T cells expressing IL-17, IL-17F, or IL-22 in the lymphoid organs of recipients of an allogeneic bone marrow transplant. We found no differences in GVHD mortality or graft-versus-tumor (GVT) activity between wild type (WT) and IL-17(-/-) T-cell recipients. However, upon transfer of murine IL-17(-/-) CD4(+) T cells in an allogeneic BMT model, GVHD development was significantly delayed behind recipients of WT CD4(+) T cells, yet overall GVHD mortality was unaffected. Moreover, recipients of IL-17(-/-) CD4(+) T cells had significantly fewer Th1 cells during the early stages of GVHD. Furthermore, we observed a decrease in the number of IFN-gamma-secreting macrophages and granulocytes and decreased production of proinflammatory cytokines (interferon [IFN]-gamma, IL-4, and IL-6) in recipients of IL-17(-/-) CD4(+) T cells. We conclude that IL-17 is dispensable for GVHD and GVT activity by whole T cells, but contributes to the early development of CD4-mediated GVHD by promoting production of proinflammatory cytokines.
authors.affiliation: Department of Medicine and Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: Lucy W
authors.initials: LW
authors.lastname: Kappel
authors.forename: Gabrielle L
authors.initials: GL
authors.lastname: Goldberg
authors.forename: Christopher G
authors.initials: CG
authors.lastname: King
authors.forename: David Y
authors.initials: DY
authors.lastname: Suh
authors.forename: Odette M
authors.initials: OM
authors.lastname: Smith
authors.forename: Cassandra
authors.initials: C
authors.lastname: Ligh
authors.forename: Amanda M
authors.initials: AM
authors.lastname: Holland
authors.forename: Jeremy
authors.initials: J
authors.lastname: Grubin
authors.forename: Nicholas M
authors.initials: NM
authors.lastname: Mark
authors.forename: Chen
authors.initials: C
authors.lastname: Liu
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Iwakura
authors.forename: Glenn
authors.initials: G
authors.lastname: Heller
authors.forename: Marcel R M
authors.initials: MR
authors.lastname: van den Brink
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D049109:Cell Proliferation; D005260:Female; D006086:Graft vs Host Disease / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D007371:Interferon-gamma / Q000097:blood; D020381:Interleukin-17 / Q000172:deficiency / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D007378:Interleukins / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D018345:Mice, Knockout; D013154:Spleen / Q000166:cytology / Q000276:immunology; D014184:Transplantation, Homologous / Q000276:immunology; D000097043:Interleukin-22
chemical_list: D007371:Interferon-gamma; D020381:Interleukin-17; D007378:Interleukins; D000097043:Interleukin-22